RxDoctor Payments DataLook up a doctor →

Manohar Jethani, MD

Family Medicine · Berwyn, ILNPI 1366529505

Payments from drug & device makers

$4,864,475in general payments, 2019–2025

Across 1,278 payments — averaging $3806.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2.2M
  • Pfizer$1.2M
  • GSK$758K
  • Sanofi Pasteur Inc.$320K
  • Novartis$221K
  • Ionis Pharmaceuticals, Inc.$82K
  • plus $112K from 52 others
$2,787in research payments, 2019–2025

Across 7 payments — averaging $398.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lexicon Pharmaceuticals, Inc.$2K
  • Sanofi Pasteur Inc.$999

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$20,65541%
  • Travel & lodging$3,4947%
  • Food & beverage$25,17851%
  • Education$4111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.164$2,172,296
Pfizer93$1,199,475
GSK116$757,692
Sanofi Pasteur Inc.6$319,716
Novartis24$220,514
Ionis Pharmaceuticals, Inc.23$82,384
AbbVie(2 entities)118$23,700
AstraZeneca63$22,834
Amarin Pharma, Inc.69$20,001
Lexicon Pharmaceuticals, Inc.3$19,656
Amgen(2 entities)88$7,239
Esperion Therapeutics, Inc.26$5,526
Novo Nordisk122$3,609
Johnson & Johnson(3 entities)29$1,463
Mylan Specialty L.p.38$909
Boehringer Ingelheim38$857
Lilly USA, LLC39$812
Bayer19$655
Merck26$580
Sanofi-aventis U.S. LLC17$549
Eli Lilly12$444
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$343
Aimmune Therapeutics, Inc.35$334
Currax Pharmaceuticals LLC23$281
Abbott4$182
Astellas Pharma US Inc3$176
Phathom Pharmaceuticals, Inc.2$161
Regeneron Healthcare Solutions, Inc.2$152
Biohaven Pharmaceutical Holding Company Ltd.6$144
Echosens North America, Inc.2$136
Exact Sciences6$131
Regeneron1$129
Kowa Pharmaceuticals America, Inc.6$126
Axsome Therapeutics, Inc.1$122
Otsuka America Pharmaceutical, Inc.1$120
Vanda Pharmaceuticals Inc.1$115
Comsort, Inc1$100
Jazz Pharmaceuticals Inc.1$85
Teva Pharmaceuticals USA, Inc.1$81
Takeda Pharmaceuticals U.S.A., Inc.5$77
Viatris Specialty LLC3$71
Arbor Pharmaceuticals, Inc.3$54
Smith+Nephew2$49
Sumitomo Pharma America, Inc.2$45
Philips North America LLC2$40
Inspire Medical Systems, Inc.1$39
Corcept Therapeutics2$37
E.r. Squibb & Sons, L.L.C.2$36
Ironshore Pharmaceuticals Inc.2$33
Medicomp Inc1$27
Xeris Pharmaceuticals, Inc.1$23
Genentech USA, Inc.1$22
Baxter Healthcare1$19
Hologic Sales And Service, LLC1$16
Vivus LLC1$16
Biohaven Pharmaceuticals, Inc.1$15
Nestle Healthcare Nutrition Inc.1$15
Agile Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,864,475 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$114,478
Medicare patients
254
Services billed
5,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$99,878
MounjaroTirzepatide86$98,095
EliquisApixaban59$80,443
JardianceEmpagliflozin64$65,713
FarxigaDapagliflozin Propanediol14$22,717
TradjentaLinagliptin15$20,622
VascepaIcosapent Ethyl22$19,638
JanuviaSitagliptin Phosphate15$16,751
Repatha SureclickEvolocumab12$15,996
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,084
Icosapent Ethyl20$4,962
Breo ElliptaFluticasone/Vilanterol12$4,876
Rosuvastatin Calcium184$3,673
Atorvastatin Calcium286$3,240
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,609$99,87874 claims
Lilly USA, LLCMounjaro$812$98,09586 claims
Boehringer IngelheimJardiance, Tradjenta$857$86,33579 claims
PfizerEliquis$1,199,475$80,44359 claims
AstraZenecaFarxiga$22,834$22,71714 claims
MerckJanuvia$580$16,75115 claims
GSKBreo Ellipta$757,692$4,87612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Berwyn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →